aegate-news3-1.jpg

December 2, 2020by @zp

On February 19th and 20th all Accredited Pharmacy Patient Medication Record Companies are invited to attend the 2015 AEGATE SAFE MEDICINE ECOSYSTEM PARTNER PROGRAM™ at  the Apollo Wyndham Hotel, Amsterdam.

The Symposium is designed to address the opportunity for the Aegate PMR Service Provider community to discover the profitable new business services that are enabled for pharmacies and the pharmacy value chain.

The Symposium Agenda: the Medicine Digital Network

  •  The Falsified Medicine Directive in the EU
  • Value creation opportunities for PMRs
  • Case Studies
  • Oxford Research Program
  • Enhancing the role of the Pharmacy in Health Care Delivery
  • New services to Pharmaceutical Companies
  • The power of the EUROPE-WIDE community of PMR Service Providers
  • Cross European Linkages
  • Exchange Forum: ideas for growth
  • Growing the industry
  • Beyond Europe

As an accredited PMR partner you can sign up to attend the symposium by confirming to Leanne Huff your interest in participating.

The venue and room and board costs will be covered by Aegate for accredited participants.

Location

Wyndham Apollo Hotel Amsterdam Apollolaan 2 1077 BA Amsterdam

Nederland


aegate-news3-1.jpg

December 2, 2020by @zp

Il 19 e 20 febbraio tutte le aziende Provider di Software per la gestione della farmacia (PMR) , sono invitate a partecipare alla conferenza-simposio che si terrà ad Amsterdam “2015 AEGATE SAFE MEDICINE ECOSYSTEM PARTNER PROGRAM™

Questo incontro si propone di analizzare le opportunità che si offrono alla comunità dei Provider di Servizi, al fine di scoprire nuove occasioni redditizie di business da applicare alle farmacie e alla catena del valore della farmacia.

Agenda del Simposio: La rete digitale dei farmaci

  • La Direttiva europea sui farmaci contraffatti (FMD)
  • Opportunità di creare Valore per le PMR
  • Case Studies
  • Programma di Ricerca di Oxford
  • Accrescere il ruolo della farmacia nel Servizio Sanitario
  • Nuovi servizi per le aziende farmaceutiche
  • Il potere della comunità europea per i produttori di software per la Farmacia (PMR)
  • Collegamenti attraverso l’Europa
  • Forum di Scambio: idee per la crescita
  • Crescita del settore
  • Al di fuori dell’Europa

In qualità di partner accreditato PMR è possibile iscriversi per partecipare al simposio confermando per Leanne Huff vostro interesse a partecipare.

I costi di location, vitto e alloggio saranno coperti da Aegate per i partecipanti accreditati.

Località

Wyndham Apollo Hotel Amsterdam Apollolaan 2 1077 BA Amsterdam

Natherlands


aegate-news2.jpg

November 30, 2020by @zp0

09 February 2010: Aegate today announced, in conjunction with the Federal Union of German Associations of Pharmacists (ABDA) a collaborative programme to evaluate the impact and benefits of an authentication system in Germany. In addition, Aegate has presented the programme to the Bundesverband der Pharmazeutischen Industrie (the German Pharmaceutical Association, BPI), and has discussed the programme in detail with BPI members.

Aegate’s service, which is already fully operational in Belgium, Greece, and Italy, enables individual medicinal packs to be authenticated by the pharmacist before dispensing, confirming items are in date, not recalled or potentially counterfeit. The system also provides the latest drug safety information to pharmacists whilst dispensing, greatly empowering the role of the pharmacist.

The flexibility of Aegate’s system enabled some key criteria to be fulfilled; ABDA and the BPI required this authentication programme to co-exist with the current reimbursement framework that is in place for Germany; they wished to be able to evaluate a 2D Data-matrix serialisation technology and also needed a simple deployment for pharmacists. Aegate’s system seamlessly integrates into the existing dispensary software that pharmacists use, ensuring easy and fast installation for pharmacies.

“The fight against counterfeit drugs is one of the most important efforts in protecting consumers,” says ABDA President Heinz-Guenter Wolf: “Pharmacists are currently making a major contribution to ensuring that patients are provided with drugs that are suitable for dispense. To be prepared in the future against the growing international crime of forgery in the highly profitable drugs market, we started this project to test a technology that can provide even more safety for the public”.

Prior to full scale implementation, the programme will last around seven months and include numerous pharmacies throughout Germany as well as 15 pharmaceutical manufacturers and wholesalers.

The timing of this programme and Aegate’s open approach to working with pharmacy and industry associations who have a variety of existing pharmaceutical frameworks for dispensing medicine, will enable a greater number of member states to evaluate and install authentication systems in line with the forthcoming European Commission’s directive on counterfeit medicines. The directive, which seeks mandatory safety features that will permit identification, authentication and traceability on all packs of medicine, is due to be completed during 2010.


aegate-news4.jpg

November 30, 2020by @zp0

London, 19 November 2009: Research published today examining consumer opinions on counterfeit drugs reveals that five per cent of consumers across five European countries suspect they have received a counterfeit prescription drug and an alarming one per cent believe they definitely have. This means that as many as 12.8 million consumers could have been exposed to fake drugs in those markets.

According to research carried out by ICM on behalf of patient safety communications company Aegate, awareness of the phony drugs market is moderate in Europe with 61 per cent saying they know prescription drugs can be faked. As a result, 79 per cent of consumers put medicine at the top of their counterfeit concern list, far ahead of any other product. Designer clothes and toys, which were the next concerns, fall far behind with four per cent each.

And it would seem their concern is justified. In December 2008, it was revealed that 34 million counterfeit pills were seized, valued at 89million Euros, by European Union customs officials between October and December 2008.

European consumers see the fake drugs trade to be largely the responsibility of medicine suppliers, with 45 per cent saying the manufacturer is responsible for the fake prescription medicine trade. They are not the only ones to be deemed liable though – 31 per cent say it’s the fault of the wholesaler and 30 per cent the pharmacist.

Worried about fake drugs finding their way into their hands, European consumers are calling for greater controls to be put in place. Eighty five per cent of consumers said they would feel more confident if medicine packs contained a safety feature that enabled the pharmacist to verify the medicine is genuine before dispensing.

In addition, 90 per cent said they would not buy drugs online if pharmacies in Europe had a tool to authenticate prescription drugs – a particularly reassuring number in light of data published by the EAASM (European Alliance for Access to Safe Medicines) that 62 per cent of drugs bought online are fake or substandard.

Consumers feel very strongly about the drug counterfeiting trade. Over two thirds stated that the penalty for counterfeiting medicines should be between five and 15 years in prison, despite the current penalties being far lower – while a fifth feel life in prison is justified.

However, despite consumers’ desire for justice and their understanding of the very real dangers of fake medicines, their response in terms of what they would do if they thought they had a counterfeit is extremely variable. Fifty-five percent of consumers said they would either throw away a suspect counterfeit drug unreported, research it on the internet, talk to family and friends or call a local newspaper. On average only 40 per cent would call their pharmacist, the police or their doctor.

“It is very different buying medication online to buying an item of clothing” commented Gary Noon, CEO, Aegate. “Patients need to be encouraged to seek medicines from their high street pharmacist who is trained and qualified to assess their medical needs as well as the medicine. Patient safety should be the industry’s priority from the regulator, to the manufacturer and to the pharmacist and it is clear we need to ensure the pharmacist has the right tools in place to carry out such an important task.”


aegate-news1.jpg

November 30, 2020by @zp0

London, United Kingdom, Nov 17, 2008: Pharmacists in Ireland will soon be the benefactors of a unique and growing European patient safety communications service, as Aegate announces that the Republic will be the fourth European market that it will enter. From 2009, pharmacists will be better equipped with a new tool that provides real-time safety information about the quality and safety of medicines at the most critical time-point, before they dispense to patients.

Through a joint venture with Irish pharmacy systems provider McLernon Computers, Irish pharmacists will join more than ten thousand pharmacists across Europe who are able to receive an upgrade to their existing pharmacy software to install Authentication at the point of dispensingTM.

Aegate’s entry into Ireland is a significant milestone for the company which, since it launched in 2006, has commenced roll-out in a new country every eight months, with operations currently existing in Belgium, Greece and Italy.

As the last point of professional contact between the patient and the pharmaceutical industry, informed and accurate communication in the pharmacy at the point of dispensing is fundamental not only to patient safety but also to the pharmacy itself. This is understood in pharmacy practice as evidenced by the strong endorsement from the professional pharmacy associations in each country in which Aegate operates, including the APB in Belgium and the Pan Hellenic Association in Greece.

Gary Noon, CEO of Aegate, said: “Our move into Ireland is indicative of the momentum Aegate is gathering across the continent and the value that our unique approach to patient safety brings.”